DRNA Dicerna Pharmaceuticals Inc.

20.12
-1.24  -6%
Previous Close 21.36
Open 21.14
Price To Book 10.27
Market Cap 1,376,832,686
Shares 68,431,048
Volume 958,349
Short Ratio
Av. Daily Volume 1,007,067
Stock charts supplied by TradingView

NewsSee all news

  1. Dicerna™ Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

    Dicerna™ Pharmaceuticals, Inc. (NASDAQ:DRNA) (the "Company" or "Dicerna"), a leading developer of investigational ribonucleic acid (RNA) interference (RNAi) therapeutics, today announced that the Compensation Committee

  2. Dicerna™ Announces Closing of Agreement With Novo Nordisk for Discovery and Development of RNAi Therapies for Liver-Related Cardio-Metabolic Diseases

    Dicerna™ Pharmaceuticals, Inc. (NASDAQ:DRNA) (the "Company" or "Dicerna"), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced the closing of the discovery and

  3. Dicerna™ Announces Closing of Worldwide Collaboration and Licensing Agreement With Roche for Treatments for Chronic Hepatitis B Virus Infection

    Dicerna™ Pharmaceuticals, Inc. (NASDAQ:DRNA) (the "Company" or "Dicerna"), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced the successful closing of the research

  4. Dicerna™ Receives Orphan Drug Designation From European Commission for DCR-A1AT for Treatment of Congenital Alpha-1 Antitrypsin Deficiency

    Dicerna™ Pharmaceuticals, Inc. (NASDAQ:DRNA) (the "Company" or "Dicerna"), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the European Commission (EC) has

  5. Alexion Exercises Option for Two Additional GalXC™ RNAi Programs for Complement-Mediated Targets Under Collaboration With Dicerna™

    – Option Exercise Triggers $20 Million Payment to Dicerna – Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) and Dicerna™ Pharmaceuticals, Inc. (NASDAQ:DRNA) today announced that Alexion has exercised its option for

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Development discontinued September 2016.
DCR-MYC
Hepatocellular carcinoma (HCC) - cancer
Phase 2/3 enrolment to be completed 1H 2020.
DCR-PHXC - PHYOX2
Primary hyperoxaluria (PH)
Phase 1 data due mid-2020.
DCR-HBVS
Hepatitis B virus (HBV)
Phase 1/2 trial to commence 4Q 2019.
DCR-A1AT
Alpha-1 antitrypsin (A1AT) deficiency-associated liver disease
Phase 1 open-label data due 1H 2020.
DCR-PHXC - PHYOX3
Primary hyperoxaluria (PH)

Latest News

  1. Dicerna™ Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

    Dicerna™ Pharmaceuticals, Inc. (NASDAQ:DRNA) (the "Company" or "Dicerna"), a leading developer of investigational ribonucleic acid (RNA) interference (RNAi) therapeutics, today announced that the Compensation Committee

  2. Dicerna™ Announces Closing of Agreement With Novo Nordisk for Discovery and Development of RNAi Therapies for Liver-Related Cardio-Metabolic Diseases

    Dicerna™ Pharmaceuticals, Inc. (NASDAQ:DRNA) (the "Company" or "Dicerna"), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced the closing of the discovery and

  3. Dicerna™ Announces Closing of Worldwide Collaboration and Licensing Agreement With Roche for Treatments for Chronic Hepatitis B Virus Infection

    Dicerna™ Pharmaceuticals, Inc. (NASDAQ:DRNA) (the "Company" or "Dicerna"), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced the successful closing of the research

  4. Dicerna™ Receives Orphan Drug Designation From European Commission for DCR-A1AT for Treatment of Congenital Alpha-1 Antitrypsin Deficiency

    Dicerna™ Pharmaceuticals, Inc. (NASDAQ:DRNA) (the "Company" or "Dicerna"), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the European Commission (EC) has

  5. Alexion Exercises Option for Two Additional GalXC™ RNAi Programs for Complement-Mediated Targets Under Collaboration With Dicerna™

    – Option Exercise Triggers $20 Million Payment to Dicerna – Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) and Dicerna™ Pharmaceuticals, Inc. (NASDAQ:DRNA) today announced that Alexion has exercised its option for

  6. Dicerna™ Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

    Dicerna™ Pharmaceuticals, Inc. (NASDAQ:DRNA) (the "Company" or "Dicerna"), a leading developer of investigational ribonucleic acid (RNA) interference (RNAi) therapeutics, today announced that the Compensation Committee

  7. Dicerna™ to Present at Evercore ISI 2nd Annual HealthCONx Conference

    Dicerna™ Pharmaceuticals, Inc. (NASDAQ:DRNA) (the "Company" or "Dicerna"), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D.,

  8. Dicerna and Novo Nordisk Enter Agreement to Discover and Develop RNAi Therapies for Liver-Related Cardio-Metabolic Diseases

    – Collaboration to Explore Liver Cell Targets Using Dicerna's GalXC™ Technology With the Potential to Deliver a Significant Number of Clinical Candidates – – Each Company to Retain Rights to Co-Develop

  9. Dicerna™ to Present at the Stifel 2019 Healthcare Conference

    Dicerna™ Pharmaceuticals, Inc. (NASDAQ:DRNA) (the "Company" or "Dicerna"), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D.,

  10. Dicerna™ Announces Third Quarter 2019 Financial Results and Reports Development Programs Progress

    — Initiated Dosing of Patients With Primary Hyperoxaluria Types 1 and 2 in PHYOX™2 Pivotal Clinical Trial — — Announced Collaboration Agreement With Roche for Development of DCR-HBVS Including Option to Co-Fund

  11. Dicerna™ to Report Third Quarter 2019 Financial Results and Host Conference Call on November 7, 2019

    Dicerna™ Pharmaceuticals, Inc. (NASDAQ:DRNA) (the "Company" or "Dicerna"), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will release its

  12. Dicerna™ Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

    Dicerna™ Pharmaceuticals, Inc. (NASDAQ:DRNA) (the "Company" or "Dicerna"), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that the Compensation Committee of the

  13. Dicerna™ Enters Agreement with Roche to Develop and Commercialize DCR-HBVS for the Treatment of Chronic Hepatitis B Virus (HBV) Infection

    – Roche to gain worldwide license to Dicerna's novel RNAi therapy currently in Phase 1 – – Dicerna to receive $200 million up front plus up to $1.47 billion in potential milestone payments related to DCR-HBVS – –

  14. Dicerna™ Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

    Dicerna™ Pharmaceuticals, Inc. (NASDAQ:DRNA) (the "Company" or "Dicerna"), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that the Compensation Committee of the

  15. Dicerna™ to Present at Two Upcoming Investor Conferences

    Dicerna™ Pharmaceuticals, Inc. (NASDAQ:DRNA) (the "Company" or "Dicerna"), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that management will present at two

  16. Dicerna™ Appoints Patrick Gray to Board of Directors to Support Continued Growth

    Company Announces Retirement of Board of Director Veteran Dennis Langer Dicerna™ Pharmaceuticals, Inc. (NASDAQ:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today

  17. Dicerna™ Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

    Dicerna™ Pharmaceuticals, Inc. (NASDAQ:DRNA) (the "Company" or "Dicerna"), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that the Compensation Committee of the

  18. Dicerna™ to Present at H.C. Wainwright 21st Annual Global Investment Conference

    Dicerna™ Pharmaceuticals, Inc. (NASDAQ:DRNA) (the "Company" or "Dicerna"), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D.,